Trial reportBlood cancer journal2021
Viral infection/reactivation during long-term follow-up in multiple myeloma patients with anti-BCMA CAR therapy.
Open access · goldAbstract readClinical TrialLetterMulticenter Study
In one paragraph
Trial report in Blood cancer journal, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed, 1 pooled it
5.1field-weighted citation impact, top 4% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 1 synthesis or guideline pooled it, 45 citations in OpenAlex.
- Best Practice Considerations by The American Society of Transplant and Cellular Therapy: Infection Prevention and Management After Chimeric Antigen Receptor T Cell Therapy for Hematological Malignancies.Transplantation and cellular therapy · 2024Guideline
- Changes in C-Reactive Protein Forecast Infection Risk Following Treatment with Chimeric Antigen Receptor T Cells.Cancers · 2026Article
- Balancing Efficacy and Safety in Multiple Myeloma Patients Receiving B cell Maturation Antigen-Directed CAR T-Cell Therapy.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2026Review
- Infections Within 100 Days of Idecabtagene Vicleucel and Impact on Survival for Relapsed/Refractory Multiple Myeloma: A CIBMTR Analysis.Transplantation and cellular therapy · 2026Article
- Review
- Influence of B cell-lineage targeted CAR-T cell therapy on humoral immunity and vaccine-induced antibody response.Nature communications · 2026Article
- Viral Reactivation in Multiple Myeloma Patients Receiving Anti-BCMA Chimeric Antigen Receptor T-Cell Therapy.International journal of molecular sciences · 2026Article
- Antibody-Drug Conjugates, T-Cell Engager Bispecific Antibodies and Chimeric Antigen Receptor T Cells for Multiple Myeloma: What's the Current Status?Targeted oncology · 2026Review
- T-Cell Redirecting Therapies in Multiple Myeloma: Pathogenesis and Management of Toxicities Beyond CRS and ICANS.Cancers · 2025Review
- Case Report: Summary of multiple CAR-T expansions in anti-BCMA/GPRC5D bispecific CAR-T cell therapy for multiple myeloma.Frontiers in immunology · 2025Article
- Cytomegalovirus Retinitis Following Daratumumab for Multiple Myeloma: A Case Report and Literature Review.Case reports in medicine · 2025Article
- Understanding the Clinical Significance of Cytomegalovirus Viremia After Chimeric Antigen Receptor T-Cell Therapy: Should We be Treating a Value?Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2024Article
- Equecabtagene Autoleucel in Patients With Relapsed or Refractory Multiple Myeloma: The FUMANBA-1 Nonrandomized Clinical Trial.JAMA oncology · 2024Article
- Incidence and outcomes of cytomegalovirus reactivation after chimeric antigen receptor T-cell therapy.Blood advances · 2024Article
- Infectious complications in pediatric patients undergoing CD19+CD22+ chimeric antigen receptor T-cell therapy for relapsed/refractory B-lymphoblastic leukemia.Clinical and experimental medicine · 2024Article
- Cytomegalovirus (CMV) Reactivation and CMV-Specific Cell-Mediated Immunity After Chimeric Antigen Receptor T-Cell Therapy.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2024Article
- Toxicities, intensive care management, and outcome of chimeric antigen receptor T cells in adults: an update.Critical care (London, England) · 2024Review
- Neutrophil activation and clonal CAR-T re-expansion underpinning cytokine release syndrome during ciltacabtagene autoleucel therapy in multiple myeloma.Nature communications · 2024Article
- Recommendations for the effective use of T-cell-redirecting therapies: a Canadian consensus statement.Frontiers in oncology · 2024Review
- Overview of infectious complications among CAR T- cell therapy recipients.Frontiers in oncology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 5 institutions in 1 country.
Di Wang *Department of Hematology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, 430030, China.
Xia Mao *Department of Hematology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, 430030, China.
Yimei QueDepartment of Hematology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, 430030, China.
Menglei XuDepartment of Hematology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, 430030, China.
Yuhang ChengDepartment of Hematology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, 430030, China.
Liang HuangDepartment of Hematology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, 430030, China.ORCID 0000-0002-8370-3232
Jue WangDepartment of Hematology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, 430030, China.
Yi XiaoDepartment of Hematology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, 430030, China.ORCID 0000-0001-7274-6774
Wen WangNanjing IASO Biotherapeutics Ltd, Nanjing, Jiangsu, 210032, China.ORCID 0000-0003-3215-3020
Guang HuNanjing IASO Biotherapeutics Ltd, Nanjing, Jiangsu, 210032, China.
Shangkun ZhangCollege of Life Science and Health, Wuhan University of Science and Technology, Wuhan, Hubei, China.
Tongcun ZhangCollege of Life Science and Health, Wuhan University of Science and Technology, Wuhan, Hubei, China.
Chunrui LiDepartment of Hematology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, 430030, China. cunrui5650@hust.edu.cn.ORCID 0000-0001-5134-7133
Jianfeng ZhouDepartment of Hematology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, 430030, China. jfzhou@tjh.tjmu.edu.cn.ORCID 0000-0002-1332-9230
Hubei Provincial Center for Disease Control and Prevention · CNChina Design Group (China) · CNWuhan Institute of Bioengineering · CNHubei Provincial Water Resources and Hydropower Planning Survey and Design Institute · CNTongji Hospital · CN
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Immunotherapy, AdoptiveMultiple MyelomaVirus DiseasesAdultAgedFemaleFollow-Up StudiesHumansMaleMiddle AgedReceptors, Chimeric AntigenRegistriesReceptors, Chimeric Antigen
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.